Leslie Michael Shaw

Leslie Michael Shaw's AcademicInfluence.com Rankings

Leslie Michael Shaw

Biology

#5607

World Rank

#8127

Historical Rank

Neuroscience

#640

World Rank

#667

Historical Rank

biology Degrees

Download Badge

Biology

Leslie Michael Shaw's Degrees

Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Leslie Michael Shaw Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Leslie Michael Shaw's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010) (3896)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers (2013) (3207)
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) (716)
Alzheimer's Disease Neuroimaging Initiative (ADNI) (2010) (712)
Activation of Phosphoinositide 3-OH Kinase by the α6β4 Integrin Promotes Carcinoma Invasion (1997) (626)
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers (2008) (579)
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification (2011) (540)
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. (2001) (466)
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease (2010) (464)
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. (2010) (446)
Relationships between biomarkers in aging and dementia (2009) (440)
The role of NFAT transcription factors in integrin-mediated carcinoma invasion (2002) (417)
Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans (2010) (395)
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance (2012) (388)
MRI and CSF biomarkers in normal, MCI, and AD subjects (2009) (384)
CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts (2018) (380)
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. (2013) (342)
Plasma tau in Alzheimer disease (2016) (337)
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease (2013) (332)
Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. (2000) (331)
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease (2010) (328)
Current state of Alzheimer’s fluid biomarkers (2018) (327)
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. (2016) (326)
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics (2007) (321)
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation (2006) (313)
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects (2010) (311)
Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. (1995) (306)
Community Exposure to Perfluorooctanoate: Relationships Between Serum Concentrations and Exposure Sources (2006) (303)
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid (2013) (300)
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative (2012) (295)
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome (2018) (288)
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI (2011) (275)
The activation dependent adhesion of macrophages to laminin involves cytoskeletal anchoring and phosphorylation of the alpha 6 beta 1 integrin (1990) (265)
The α6β4 integrin and epithelial cell migration (2001) (260)
The major non-integrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac-2). (1990) (250)
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. (1996) (238)
Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. (1997) (236)
Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies (2003) (235)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative (2018) (225)
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. (2000) (224)
Evidence for ordering of Alzheimer disease biomarkers. (2011) (217)
Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. (2015) (211)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research (2015) (205)
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. (2015) (204)
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease (2012) (202)
Identification of Insulin Receptor Substrate 1 (IRS-1) and IRS-2 as Signaling Intermediates in the α6β4 Integrin-Dependent Activation of Phosphoinositide 3-OH Kinase and Promotion of Invasion (2001) (193)
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. (2012) (189)
Human Alzheimer and Inflammation Biomarkers after Anesthesia and Surgery (2011) (189)
Integrin (α6β4) regulation of eIF-4E activity and VEGF translation (2002) (185)
MRI and CSF biomarkers in normal, MCI, and AD subjects (2009) (181)
Community Exposure to Perfluorooctanoate: Relationships Between Serum Levels and Certain Health Parameters (2006) (180)
Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. (1990) (174)
Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition (2009) (173)
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases (2012) (171)
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI (2013) (170)
Longitudinal change of biomarkers in cognitive decline. (2011) (169)
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study (2016) (169)
Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment (2010) (168)
A description of two procedures which avoid the use of extreme pH conditions for the resolution of components isolated from chromatins prepared from pig cerebellar and pituitary nuclei. (1970) (168)
Cannabinoids and appetite stimulation (1994) (166)
Release of cAMP Gating by the α6β4 Integrin Stimulates Lamellae Formation and the Chemotactic Migration of Invasive Carcinoma Cells (1998) (165)
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. (2011) (164)
Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. (2002) (161)
Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses (2003) (157)
Expression and function of the insulin receptor substrate proteins in cancer (2009) (154)
Ethylene glycol poisoning: toxicokinetic and analytical factors affecting laboratory diagnosis. (1998) (153)
The Effect of Renal Insufficiency on Mycophenolic Acid Protein Binding (1999) (152)
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers (2018) (151)
Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease (2019) (150)
Mouse egg integrin alpha 6 beta 1 functions as a sperm receptor. (1995) (149)
A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank (2014) (148)
Clinical and multimodal biomarker correlates of ADNI neuropathological findings (2013) (147)
Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients (2001) (147)
Characterizing Alzheimer's disease using a hypometabolic convergence index (2011) (145)
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology (2019) (141)
Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis (2012) (140)
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) (2013) (137)
GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation (2013) (136)
Mycophenolic Acid Area under the Curve Values in African American and Caucasian Renal Transplant Patients Are Comparable (2000) (136)
Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. (2013) (136)
Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. (2002) (134)
Therapeutic monitoring of mycophenolic acid. A consensus panel report. (1998) (132)
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease (2018) (132)
Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium (2013) (131)
Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders (2019) (130)
THERAPEUTIC DRUG MONITORING OF CYCLOSPORINE AND TACROLIMUS (1998) (129)
Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. (1998) (127)
The alpha 6 beta 4 integrin and epithelial cell migration. (2001) (126)
Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis (2004) (126)
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects (2010) (126)
Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. (2000) (126)
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. (2012) (126)
Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. (1986) (122)
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker (2013) (121)
Approved Recommendation (1985) on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes (2009) (118)
Current opinions on therapeutic drug monitoring of immunosuppressive drugs. (1999) (117)
Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers (2017) (117)
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition (2011) (116)
Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers☆☆☆ (2013) (115)
Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls (2009) (114)
IFCC methods for the measurement of catalytic concentration of enzymes Part 5. IFCC method for alkaline phosphatase (orthophosphoric-monoester phosphohydrolase, alkaline optimum, EC 3.1.3.1). (1983) (114)
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort (2018) (113)
Multicenter, Randomized Study of the Use of Everolimus With Tacrolimus After Renal Transplantation Demonstrates its Effectiveness (2008) (112)
Mycophenolate Mofetil: A Report of the Consensus Panel (1995) (112)
The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation (2005) (112)
Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. (2001) (110)
Tumor cell invasion assays. (2005) (108)
Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel. (1990) (107)
RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion (2000) (107)
The insulin receptor substrate (IRS) proteins (2011) (107)
Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers (2019) (106)
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. (2015) (106)
Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology (2018) (106)
The integrin alpha 6 beta 1 promotes the survival of metastatic human breast carcinoma cells in mice. (1997) (105)
Divergent Roles for IRS-1 and IRS-2 in Breast Cancer Metastasis (2007) (104)
Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features (2017) (104)
Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative (2012) (103)
Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study (2010) (101)
Pharmacokinetics of mycophenolic acid in renal insufficiency. (2000) (100)
Regulation of Mitogen-activated Protein Kinase Activation by the Cytoplasmic Domain of the α6 Integrin Subunit* (1998) (99)
CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation. (2017) (99)
Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. (2012) (98)
Regulated splicing of the α6 integrin cytoplasmic domain determines the fate of breast cancer stem cells. (2014) (98)
Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis (2006) (98)
Inside-out integrin signaling in macrophages. Analysis of the role of the alpha 6A beta 1 and alpha 6B beta 1 integrin variants in laminin adhesion by cDNA expression in an alpha 6 integrin-deficient macrophage cell line. (1993) (97)
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (96)
Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. (2014) (96)
Evidence that Distinct States of the Integrin α6β1 Interact with Laminin and an ADAM (1999) (95)
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease (2014) (93)
Function of the integrin α6β1 in metastatic breast carcinoma cells assessed by expression of a dominant-negative receptor (1996) (93)
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid (2011) (92)
Human pharmacokinetics of WR-2721. (1986) (92)
Machine learning for comprehensive forecasting of Alzheimer’s Disease progression (2018) (92)
Mycophenolic acid concentrations are associated with cardiac allograft rejection. (2000) (92)
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition (2014) (91)
Drosophila Sirt2/mammalian SIRT3 deacetylates ATP synthase β and regulates complex V activity (2014) (90)
Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. (2015) (89)
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease (2013) (89)
Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. (2012) (85)
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls (2017) (85)
Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. (2012) (84)
Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays (2019) (84)
Integrin Laminin Receptors and Breast Carcinoma Progression (2001) (83)
The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. (2002) (83)
International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring (2002) (81)
Advances in cyclosporine pharmacology, measurement, and therapeutic monitoring. (1989) (81)
Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease (2010) (81)
The underreporting of cocaine-related trauma: drug abuse warning network reports vs hospital toxicology tests. (1993) (81)
Pharmacokinetics of WR-2721. (1988) (81)
Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. (1998) (80)
Macrophage interactions with laminin: PMA selectively induces the adherence and spreading of mouse macrophages on a laminin substratum (1988) (79)
Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology (2018) (78)
HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. (2007) (76)
Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease (2019) (76)
Regulation of cellular interactions with laminin by integrin cytoplasmic domains: the A and B structural variants of the alpha 6 beta 1 integrin differentially modulate the adhesive strength, morphology, and migration of macrophages. (1994) (76)
Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients (2009) (73)
The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans (2015) (72)
Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome (2020) (71)
Isolation of gamma-glutamyltransferase from human liver, and comparison with the enzyme from human kidney. (1978) (71)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. (2010) (70)
Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns (2017) (69)
Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. (1994) (67)
Fimbrin localized to an insoluble cytoskeletal fraction is constitutively phosphorylated on its headpiece domain in adherent macrophages. (1993) (65)
Pharmacokinetics of amifostine: effects of dose and method of administration. (1999) (65)
Bypassing the first-pass effect for the therapeutic use of cannabinoids (1993) (64)
Regulation of alpha 6 beta 1 integrin laminin receptor function by the cytoplasmic domain of the alpha 6 subunit (1993) (64)
Can WR-2721 be improved upon? (1988) (64)
Integrin Function in Breast Carcinoma Progression (1999) (63)
CSF Apo-E levels associate with cognitive decline and MRI changes (2014) (63)
Emerging β-amyloid pathology and accelerated cortical atrophy. (2014) (63)
Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. (2006) (63)
International Federation of Clinical Chemistry, (IFCC), Scientific Committee, Analytical Section. IFCC methods for the measurement of catalytic concentration of enzymes. Part 4. IFCC method for gamma-glutamyltransferase [(gamma-glutamyl)-peptide: amino acid gamma-glutamyltransferase, EC 2.3.2.2]. (1983) (63)
Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative (2015) (62)
Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease. (2012) (62)
Selenium detoxification is required for cancer cell survival (2020) (61)
Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. (1994) (61)
Beclin 1 regulates growth factor receptor signaling in breast cancer (2014) (60)
Role of Insulin Receptor Substrates and Protein Kinase C-ζ in Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Pancreatic Cancer Cells* (2004) (60)
Mycophenolic Acid: Measurement and Relationship to Pharmacologie Effects (1995) (60)
Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. (1996) (60)
Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease (2017) (60)
Cerebrospinal fluid tau, Aβ, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration (2018) (60)
Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease (2012) (59)
CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline (2018) (59)
CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders (2018) (59)
GLI1 regulates a novel neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to breast cancer initiation (2014) (58)
Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease (2017) (58)
An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. (2010) (58)
CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders (2013) (57)
Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline (2010) (57)
Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net (2011) (57)
New approaches to cyclosporine monitoring raise further concerns about analytical techniques. (2000) (56)
Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. (1998) (55)
Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism (2016) (55)
Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer’s disease in veterans, using the Alzheimer’s Disease Neuroimaging Initiative (2014) (55)
PENN Biomarker Core of the Alzheimer’s Disease Neuroimaging Initiative (2007) (55)
Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements (2016) (54)
Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. (2014) (54)
A key tyrosine (Y1494) in the beta4 integrin regulates multiple signaling pathways important for tumor development and progression. (2008) (54)
Colchicine poisoning: report of a fatal case with body fluid analysis by GC/MS and histopathologic examination of postmortem tissues. (1991) (54)
Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel (2013) (54)
Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. (1997) (54)
Plasma biomarkers of depressive symptoms in older adults (2012) (53)
Intrinsic Signaling Functions of the β4 Integrin Intracellular Domain* (2007) (53)
Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease (2013) (53)
Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation (2020) (52)
Monitoring of Mycophenolic Acid in Clinical Transplantation (2002) (52)
Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging (2016) (52)
A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes (2018) (51)
Sex differences in the genetic predictors of Alzheimer's pathology. (2019) (51)
Using Established Immunosuppressant Therapy Effectively: Lessons from the Measurement of Mycophenolic Acid Plasma Concentrations (2004) (50)
Cyclosporine bioavailability in heart-lung transplant candidates with cystic fibrosis. (1990) (50)
Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. (2019) (50)
The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer's Disease: Results of a Randomized Trial. (2016) (50)
SHP2 Mediates the Localized Activation of Fyn Downstream of the α6β4 Integrin To Promote Carcinoma Invasion (2010) (49)
Interferon gamma and lipopolysaccharide promote macrophage adherence to basement membrane glycoproteins (1989) (49)
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease (2012) (47)
Coacaethylene levels in patients who test positive for cocaine. (1996) (47)
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor (2016) (47)
Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. (2009) (46)
Round robin test on quantification of amyloid-β 1–42 in cerebrospinal fluid by mass spectrometry (2016) (46)
Pharmacokinetic profile of amifostine. (1996) (46)
Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus (2012) (46)
Insulin Receptor Substrate-2 Regulates Aerobic Glycolysis in Mouse Mammary Tumor Cells via Glucose Transporter 1* (2009) (46)
Cocaine and its metabolites constrict cerebral arterioles in newborn pigs. (1993) (46)
Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease (2018) (45)
Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults (2014) (45)
Anticholinergic toxicity associated with lupine seeds as a home remedy for diabetes mellitus. (1999) (45)
New Dosing Regimens for Amifostine: A Pilot Study to Compare the Relative Bioavailability of Oral and Subcutaneous Administration with Intravenous Infusion (2002) (45)
The transitional association between β-amyloid pathology and regional brain atrophy (2014) (44)
Immunochemical evaluation of the organ specificity of prostatic acid phosphatase. (1981) (43)
A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. (2002) (43)
Relationship of steady-state serum concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects. (1987) (43)
Sensitive, High Throughput HPLC-MS/MS Method With On-line Sample Clean-up for Everolimus Measurement (2006) (43)
Insulin Receptor Substrate 2-mediated Phosphatidylinositol 3-kinase Signaling Selectively Inhibits Glycogen Synthase Kinase 3β to Regulate Aerobic Glycolysis* (2014) (43)
Hypoxia regulates insulin receptor substrate-2 expression to promote breast carcinoma cell survival and invasion. (2009) (43)
IOP1, a novel hydrogenase-like protein that modulates hypoxia-inducible factor-1alpha activity. (2007) (43)
Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment (2019) (43)
The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. (2008) (42)
Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals (2014) (42)
Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease (2016) (42)
Gamma-Glutamyltransferase: kinetic properties and assay conditions when gamma-glutamyl-4-nitroanilide and its 3-carboxy derivative are used as donor substrates. (1977) (41)
Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. (1998) (40)
Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients (2009) (40)
Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI (2013) (40)
ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease (2014) (40)
Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. (2015) (40)
Sex-specific genetic predictors of Alzheimer’s disease biomarkers (2018) (40)
Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage? (2013) (39)
Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid. (1985) (39)
Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures (2015) (39)
Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. (1998) (38)
Biomarkers in frontotemporal lobar degenerations—Progress and challenges (2011) (38)
A Liquid Chromatographic Electrochemical Assay for S-2-(3-Aminopropylamino) Ethylphosphorothioate (WR2721) in Human Plasma (1984) (38)
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study (2020) (38)
Hydrolysis of WR2721 by mouse liver cell fractions. (1987) (38)
Measurements of auto‐antibodies to α‐synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease (2018) (37)
Therapeutic drug monitoring of mycophenolic acid. (2007) (37)
APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease (2018) (37)
Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease (2016) (37)
Alzheimers disease biomarkers: from concept to clinical utility (2008) (36)
Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study (2015) (36)
Routine monitoring of cyclosporine in whole blood and in kidney tissue using high performance liquid chromatography. (1986) (36)
The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction (2019) (36)
Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease (2018) (36)
Mining Outcome-relevant Brain Imaging Genetic Associations via Three-way Sparse Canonical Correlation Analysis in Alzheimer’s Disease (2017) (36)
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease (2020) (36)
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team (2016) (35)
Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study (2018) (35)
Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. (2011) (35)
The metastatic odyssey: the integrin connection. (2001) (35)
Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia. (1999) (35)
Electrophoretic, kinetic, and immunoinhibition properties of gamma-glutamyltransferase from various tissues compared. (1980) (34)
Pharmacokinetic analysis of a case of isopropanol intoxication. (1985) (34)
Large-scale genomics unveil polygenic architecture of human cortical surface area (2015) (34)
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents (2011) (34)
FASTKD2 is associated with memory and hippocampal structure in older adults (2014) (33)
Is the Volume of Distribution of Digoxin Reduced in Patients with Renal Dysfunction? Determining Digoxin Pharmacokinetics by Fluorescence Polarization Immunoassay (1997) (33)
CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease? (2014) (33)
Determination of the mechanism and kinetic constants for hog kidney gamma-glutamyltransferase. (1976) (32)
An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia (2016) (32)
The Effect of Lidocaine on the Ventilatory Response to Carbon Dioxide (1983) (31)
Measurement of S-2-(3-Aminopropylamino)ethanethiol (WR1065) in Blood and Tissues (1986) (31)
Low Plasma ApoE Levels Are Associated with Smaller Hippocampal Size in the Alzheimer's Disease Neuroimaging Initiative Cohort (2014) (31)
Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults. (1994) (31)
BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants (2017) (31)
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration (2019) (31)
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration (2020) (30)
Memory, executive, and multidomain subtle cognitive impairment (2015) (30)
Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment (2015) (30)
Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. (2019) (29)
A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. (2018) (28)
Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring dimension RxL clinical chemistry analyzer. (2002) (28)
Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. (2012) (28)
Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
The Effect of Propofol vs. Isoflurane Anesthesia on Postoperative Changes in Cerebrospinal Fluid Cytokine Levels: Results from a Randomized Trial (2017) (28)
Regulated splicing of the alpha6 integrin cytoplasmic domain determines the fate of breast cancer stem cells (2019) (28)
Multicenter Evaluation of a New Inosine Monophosphate Dehydrogenase Inhibition Assay for Quantification of Total Mycophenolic Acid in Plasma (2008) (27)
Topical application of WR-2721 achieves high concentrations in the rectal wall. (1995) (27)
Function of the integrin alpha 6 beta 1 in metastatic breast carcinoma cells assessed by expression of a dominant-negative receptor. (1996) (27)
Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers (2021) (27)
Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer's disease. (2019) (27)
Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit. (1988) (27)
Serum triglycerides in Alzheimer disease (2020) (26)
High-Performance Liquid Chromatography-Mass Spectroscopy/Mass Spectroscopy Method for Simultaneous Quantification of Total or Free Fraction of Mycophenolic Acid and its Glucuronide Metabolites (2009) (26)
Diagnostic accuracy of four assays of prostatic acid phosphatase. Comparison using receiver operating characteristic curve analysis. (1985) (26)
Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. (2009) (26)
Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK506) in whole blood. (1999) (26)
Increased serum bromide concentration after halothane anesthesia in man. (1975) (26)
The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease (2018) (25)
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration (2019) (25)
Design of comprehensive Alzheimer's disease centers to address unmet national needs (2010) (25)
Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup. (2010) (25)
Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. (2008) (25)
Accidental intravenous colchicine poisoning. (2004) (24)
High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. (1997) (24)
Can MRI screen for CSF biomarkers in neurodegenerative disease? (2013) (24)
First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays (2020) (24)
Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease (2017) (24)
Validated LC-MS/MS method for quantification of gabapentin in human plasma: application to pharmacokinetic and bioequivalence studies in Korean volunteers. (2007) (23)
Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome (2016) (23)
Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers. (2016) (23)
Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment (2014) (23)
International Federation of Clinical Chemistry. Scientific Committee, Analytical Section. Expert Panel on Enzymes. IFCC methods for measurement of enzymes. Part 4. IFCC methods for gamma-glutamyltransferase [(gamma-glutamyl)-peptide: amino acid gamma-glutamyltransferase, EC 2.3.2.2]. IFCC Document, (1983) (23)
History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. (2014) (23)
Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults (2020) (22)
An autophagy-independent function of Beclin 1 in cancer (2016) (22)
Development of a Pharmacokinetic and Bayesian Optimal Sampling Model for Individualization of Oral Busulfan in Hematopoietic Stem Cell Transplantation (2006) (22)
Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard. (2013) (22)
Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease (2016) (22)
ATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degeneration (2019) (22)
Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting (2018) (22)
An evaluation of a kinetic acid phosphatase method. (1977) (22)
The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. (1999) (22)
The Activation Dependent Adhesion of Macrophages to Laminin Involves Cytoskeletal Anchoring and Phosphorylation of the oL6/31 Integrin (2002) (22)
Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry. (1991) (21)
IMMUNOLOGICAL AND CLINICAL SPECIFICITY OF THE IMMUNOCHEMICAL DETERMINATION OF PROSTATIC ACID PHOSPHATASE (1982) (21)
18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults (2020) (21)
Alzheimer disease: CSF biomarkers for Alzheimer disease — approaching consensus (2017) (21)
Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys. (2002) (21)
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease (2018) (21)
Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers. (2009) (21)
Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension. (2018) (20)
Analytic Aspects of Cyclosporine Monitoring, on Behalf of the IFCC/IATDMCT Joint Working Group (2004) (20)
Serum lactate and lactate dehydrogenase in high concentrations interfere in enzymatic assay of ethylene glycol. (1996) (20)
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007. (2007) (20)
Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features (2017) (20)
Pharmacogenetic differences and drug–drug interactions in immunosuppressive therapy (2005) (20)
Predominance of native cyclosporine over metabolites in rat blood and tissue. (1988) (20)
Effect of halothane anesthesia on muscle, liver, thyroid, and adrenal-function tests in man. (1976) (20)
A systematic approach to enzyme assay optimization illustrated by aminotransferase assays. (1975) (19)
The Clinical Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation (2001) (19)
A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data (2019) (19)
Evaluation of Tricyclic Antidepressant False Positivity in a Pediatric Case of Cyproheptadine (Periactin) Overdose (2003) (19)
Nighttime dosing assures postdistribution sampling for therapeutic drug monitoring of digoxin. (1996) (19)
Hydrolysis of glutathione by human liver gamma-glutamyltransferase. (1979) (19)
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint (2019) (18)
Diversity of insulin and IGF signaling in breast cancer: Implications for therapy (2021) (18)
Adjustment of cyclosporine dosage in renal transplant patients based on concentration measured specifically in whole blood: clinical outcome results and diagnostic utility. (1990) (18)
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint (2019) (18)
Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau) (2019) (18)
ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration (2020) (17)
Determination of Azelastine in Human Plasma by Validated Liquid Chromatography Coupled to Tandom Mass Spectrometry (LC-ESI/MS/MS) for the Clinical Studies (2010) (17)
CEREBROSPINAL FLUID TAU, Aβ, AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION (2018) (17)
Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias (2021) (17)
Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study. (2009) (17)
Removal of gadolinium by peritoneal dialysis. (2008) (17)
Hydrolysis of S-2-(3-aminopropylamino)ethylphosphorothioate (WR-2721). (1986) (17)
Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease (2020) (17)
Application of response surface methodology to the assay of gamma-glutamyltransferase. (1982) (16)
Mycophenolic Acid Exposure in High- and Low-Weight Renal Transplant Patients After Dosing With Mycophenolate Mofetil in the Opticept Trial (2010) (16)
Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview. (2000) (16)
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease (2021) (16)
A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer. (1998) (16)
Development of a Predictive Limited Sampling Strategy for Estimation of Mycophenolic Acid Area Under the Concentration Time Curve in Patients Receiving Concomitant Sirolimus or Cyclosporine (2008) (16)
Beclin 1 promotes endosome recruitment of hepatocyte growth factor tyrosine kinase substrate (HRS) to suppress tumor proliferation. (2019) (16)
IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma. (2018) (16)
Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. (1998) (16)
Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies (2014) (16)
Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC) (2019) (16)
Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (15)
Serum triglycerides in Alzheimer’s disease: Relation to neuroimaging and CSF biomarkers (2018) (15)
Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. (1993) (15)
Coalition Against Major Diseases (2013) (15)
Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cells (2017) (15)
Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment. (2010) (15)
Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography. (2000) (14)
A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. (2009) (14)
The Effect of Lidocaine Infusion on the Ventilatory Response to Hypoxia (1984) (14)
Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects. (2012) (14)
Prevention of diabetes in BB rats by intermittent administration of cyclosporine. (1987) (14)
METHOD COMPARISON OF AB(1-42) MEASURED IN HUMAN CEREBROSPINAL FLUID SAMPLES BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, THE INNO-BIA ALZBIO3 ASSAY, AND THE ELECSYS® B-AMYLOID(1-42) ASSAY (2016) (14)
Pharmacokinetics and effect of cocaine on cerebral blood flow in the newborn. (1993) (14)
Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes (2011) (14)
RUNX1 and breast cancer (2017) (14)
Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. (2008) (14)
Suppression of proliferation and phosphorylation of Jak3 and STAT5 in malignant T-cell lymphoma cells by derivatives of octylamino-undecyl-dimethylxanthine. (1998) (14)
Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer (2016) (13)
Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2 (2018) (13)
Laboratory assessment of poisoning with a carbamate insecticide. (1988) (13)
Clinically silent Alzheimer's and vascular pathologies influence brain networks supporting executive function in healthy older adults (2017) (12)
A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease (2016) (12)
Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding (2015) (12)
Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. (2019) (12)
Tau pathology associates with in vivo cortical thinning in Lewy body disorders (2020) (12)
Scientific principles for mycophenolic acid therapeutic drug monitoring. (1998) (12)
Suppressor Gene in Human Colon Cancer as a Differentiation-related , Putative Metastatic Drg-1 Updated (2000) (12)
Release of cAMP gating by the alpha6beta4 integrin stimulates lamellae formation and the chemotactic migration of invasive carcinoma cells (2017) (12)
Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors (2016) (12)
Cyclosporine monitoring. (1989) (12)
Effect of plasma exchange on phenytoin plasma concentration. (1986) (12)
Cyclosporine Monitoring With 2-Hour Postdose Levels in Heart Transplant Recipients (2005) (11)
Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. (1997) (11)
Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. (1990) (11)
Evaluation of Performance of New, Isotopically Labeled Internal Standard ([13c2d4]RAD001) for Everolimus Using a Novel High-Performance Liquid Chromatography Tandem Mass Spectrometry Method (2011) (11)
AMYLOID-PET CONCORDANCE OF ELECSYS® CSF BIOMARKER IMMUNOASSAYS FOR ALZHEIMER’S DISEASE (2017) (11)
Development of a stable reference material for prostatic acid phosphatase. (1984) (11)
A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil (2006) (11)
Massive theophylline overdose with atypical metabolic abnormalities. (1990) (11)
Analysis of whole blood tacrolimus concentrations in liver transplant patients exhibiting impaired liver function. (1999) (11)
APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points. (2019) (11)
A study of the enzymatic reactions involved in the formation of 5-hydroxy-4-ketohexanoic acid and its isomer, 5-keto-4-hydroxyhexanoic acid. (1968) (10)
Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. (2020) (10)
Factors affecting the binding of disopyramide to serum proteins. (1985) (10)
Pharmacokinetics of amifostine (1999) (10)
Pharmacokinetics and Bioequivalence Study of Two Brands of Loxoprofen Tablets in Healthy Volunteers (2007) (10)
Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers. (2009) (10)
Electrophysiologic study for ventricular arrhythmia: effect on total and myocardial-specific creatine kinase activity. (1982) (10)
Diurnal variation of cyclosporine clearance in stable renal transplant recipients receiving continuous infusion. (1995) (10)
Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. (2012) (10)
FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2020) (9)
The effect of phenobarbital and methylprednisolone on the biotransformation of cyclosporine in the rat. (1988) (9)
Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans (2020) (9)
INCLUSION OF PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY IN SOLANEZUMAB EXPEDITION 3 USING FLORBETAPIR PET IMAGING OR INNO-BIA ALZBIO3 CSF Aβ1-42 (2014) (9)
Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method. (2007) (9)
Rapid quantification of levosulpiride in human plasma using RP-HPLC-MS/MS for pharmacokinetic and bioequivalence study. (2009) (9)
Cyclosporine metabolites: are they active? (1990) (9)
Interaction of γ-glutamyltransferase from human tissues with insolubilized lectins (1979) (9)
Mycophenolate Mofetil: Pharmacokinetic Strategies for Optimizing Immunosuppression (1997) (8)
Determination of Paroxetine in Plasma by Liquid Chromatography Coupled to Tandem Mass Spectrometry for Pharmacokinetic and Bio equivalence Studies (2007) (8)
The Integrin a6f31 Promotes the Survival of Metastatic Human Breast Carcinoma Cells in Mice (2007) (8)
Stability of mycophenolic acid in plasma samples from patients during mycophenolate mofetil therapy. (2003) (8)
Detection and measurement of the disulfide WR33278 [NH2(CH2)3NHCH2CH2S-]2 in blood and tissues (1987) (8)
Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. (1992) (8)
Shapes of the Trajectories of Five Major Biomarkers of Alzheimer’s Disease (2013) (7)
Is the glucuronide metabolite of MPA pharmacologically active? (1997) (7)
Effect of phenobarbital on serum and biliary parameters in a patient with Crigler-Najjar syndrome, type II and acquired cholestasis (1983) (7)
Effect of Several Variables on the In Vitro Binding of Disopyramide to Serum Proteins (1984) (7)
Regulation of alpha 6 beta 1 integrin-mediated migration in macrophages. (1995) (7)
The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients (2013) (7)
Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. (2020) (7)
Progress curve algorithm for calculating enzyme activities from kinetic assay spectrophotometric measurements. (1977) (6)
Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. (2019) (6)
Modification of WR-2721 toxicity and radioprotection by an inhibitor of alkaline phosphatase. (1986) (6)
Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. (2012) (6)
IFCC methods for the measurement of catalytic concentration of enzymes. IV: IFCC method for γ-glutamyltransferase (1983) (6)
Prostatic acid phosphatase measurement: its role in detection and management of prostatic cancer. (1982) (6)
IFCC methods for measurement of enzymes . IX: IFCC method for γ-glutamyltransferase [(γ-glutamyl)-peptide:amino acid γ-glutamyltransferase, EC 2.3.2.2.] (1983) (5)
Inter-laboratory variation when using a unified test procedure for INNO-BIA AlzBio3 (2013) (5)
18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease. (2020) (5)
Transforming CSF A β 42 measures into calculated Pittsburgh Compound B ( PIBcalc ) units of brain A β amyloid (2011) (5)
OPTICEPT TRIAL: EFFICACY AND SAFETY OF MONITORED MMF IN COMBINATION WITH CNI IN RENAL TRANSPLANTATION AT 1 AND 2 YEARS: 862 (2008) (5)
RUNX 1 and breast cancer (2018) (5)
Optimal α-Oxobutyrate Concentration for Assay of α-Hydroxybutyrate Dehydrogenase Activity in Normal and Pathological Sera at 30 °C (1974) (5)
Therapeutic Drug Monitoring for Immunosuppressive Agents (2012) (4)
The Alzheimer’s Disease Metabolome: Effects of Sex and APOE ε4 genotype (2019) (4)
The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide. (1987) (4)
Alzheimer disease Cerebrospinal Fluid biomarker in Cognitively Normal Subjects : Multicenter 1 Study 2 (2015) (4)
Performance of Two Fentanyl Immunoassays Against a Liquid Chromatography-Tandem Mass Spectrometry Method. (2020) (4)
Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients. (1997) (4)
Association of plasma and cortical beta-amyloid is modulated by APOE ε4 status. (2014) (4)
AlzheimerÃ¢ÂÂs and ParkinsonÃ¢ÂÂs Diseases Face Common Challenges inTherapeutic Development: Role of the Precompetitive Consortium,Coalition Against Major Diseases (2015) (4)
Comparison of Cerebrospinal Fluid Levels of Tau and A 1-42 in Alzheimer's Disease and Frontotemporal Degeneration Using Two Analytical Platforms (P02.055) (2012) (4)
Evaluation of liver function: A multifaceted approach to clinical diagnosis (1978) (4)
Malaria reactivated by pregnancy. (1985) (4)
Quantitation of tacrolimus in whole blood using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS). (2010) (4)
Isolationof ‘ y-Glutamyltransferasefrom Human Liver , and Comparison with the Enzyme from Human Kidney (2004) (4)
Mapre2 as a novel Alzheimer's disease target gene from gwas of CSF amyloid beta 1-42, tau and hyperphosphorylated tau in the ADNI cohort (2015) (4)
Alzheimer’s disease biomarkers: walk with deliberate haste, don’t run blithely on? (2013) (3)
Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. (2016) (3)
Quantitative analysis of tiropramide in human plasma by gas chromatography coupled to mass spectrometry for application to a bioequivalence test. (2006) (3)
Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. (2020) (3)
Effect of dopamine antagonism on the behavioral and hemodynamic responses to cocaine in piglets. (1996) (3)
ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS (2018) (3)
Intrinsic Signaling Functions of the ! 4 Integrin (2007) (3)
Ethanol, morphine and barbiturate alter the hemodynamic and cerebral response to cocaine in newborn pigs. (1995) (3)
Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803–810 (2014) (2014) (3)
Transforming CSF Aβ42 measures of brain beta-amyloid into calculated PIB (PIBcalc) units (2010) (3)
APOE effect on Alzheimer’s biomarkers in older adults with significant memory concern (2015) (3)
Interaction of gamma-glutamyltransferase from human tissues with insolubilized lectins. (1979) (3)
Evidence that distinct states of the integrin alpha6beta1 interact with laminin and an ADAM (2017) (3)
Quantitation of sirolimus using liquid chromatography-tandem mass spectrometry (LC-MS-MS). (2010) (3)
Regulated splicing of the alpha 6 integrin cytoplasmic domain determines the fate of breast cancer stem cells (2014) (3)
Proceedings of the International Consensus Conference on Immunosuppressive Drugs. Lake Louise, Alberta, Canada, May 5-7, 1995. (1995) (3)
RELATIONSHIP OF MYCOPHENOLIC ACID AREA UNDER THE CONCENTRATION‐TIME CURVE AND POST‐DOSE MYCOPHENOLIC ACID LEVELS IN HEART TRANSPLANT RECIPIENTS.: Abstract# 694 (2000) (3)
Correlates and Predictors of Cerebrospinal Fluid Cholesterol Efflux Capacity from Neural Cells, a Family of Biomarkers for Cholesterol Epidemiology in Alzheimer's Disease. (2020) (3)
A Biomarker for Concussion: The Good, the Bad, and the Unknown. (2020) (3)
211 AMIFOSTINE (AMI) PHARMACOKINETICS (PK) IN CANCER PATIENTS: DEVELOPMENT OF A POPULATION MODEL (1997) (3)
Standard Reference Materials: The measurement of the catalytic (activity) concentration of seven enzymes in NBS human serum SRM 909 (1983) (3)
CHANGES IN LIDOCAINE PROTEIN BINDING MAY EXPLAIN ITS INCREASED CNS TOXICITY AT ELEVATED CO2TENSIONS (1984) (3)
ANALYSIS OF WHOLE BLOOD TACROLIMUS CONCENTRATIONS IN LIVER TRANSPLANT PATIENTS EXHIBITING CHOLESTASIS WITH THE PRO-TRAC™ II ELISA. (1999) (2)
NO PHARMACOKINETIC INTERACTION EVIDENT IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS TREATED WITH EVEROLIMUS, BASILIXIMAB AND REDUCED TACROLIMUS EXPOSURE FOR 6 MONTHS. (2006) (2)
NONLINEAR N-SCORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM THE NATIONAL ALZHEIMER’S COORDINATING CENTER (NACC) DATASET (2018) (2)
Influence of rare reelin variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer’s disease (2015) (2)
A Rapid Nanoparticle Immunoassay to Quantitate Busulfan In Plasma (2009) (2)
EXPLORING THE NEED FOR ROBUST BIOMARKER ASSAYS IN ALZHEIMER’S DISEASE AND OTHER NEURODEGENERATIVE DISEASES (2019) (2)
Perceived Stress is Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in African Americans with Mild Cognitive Impairment. (2020) (2)
Evaluation of a Nanoparticle-Based Busulfan Immunoassay for Rapid Analysis on Routine Clinical Analyzers (2021) (2)
Ventricular maps in 804 subjects correlate with cognitive decline, CSF pathology, and imminent Alzheimer's disease (2010) (2)
Advances in Brief Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells 1 (2001) (2)
ESCITALOPRAM DECREASES LONGITUDINAL CSF ABETA CONCENTRATION IN COGNITIVELY NORMAL SUBJECTS AGE 60-85 (2016) (2)
SIMULTANEOUS DETERMINATION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE IN HUMAN PLASMA USING A SIMPLE HIGH-CHROMATOGRAPHY PROCEDURE (1998) (2)
FK-506 therapeutic drug monitoring. (1994) (2)
An innovative site for fetal pancreas transplantation in rats--the subserosa of a U loop of small intestine. (1989) (2)
IMPAIRED RENAL FUNCTION, NOT ETHNICITY, ALTERS MYCOPHENOLIC ACID PHARMACOKINETICS IN AFRICAN-AMERICAN RENAL TRANSPLANT PATIENTS (1999) (1)
The Role of Therapeutic Drug Monitoring in Disease Management: Introduction (1998) (1)
CHARACTERISTICS AND PROGRESS ON THE INITIAL 209 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL (2017) (1)
Prospective quality-control monitoring in the context of a clinical trial (2015) (1)
Iv Busulfan Administered Q12 Vs Q6 Hrs During Conditioning of Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients Has Comparable Pharmacokinetics and Significant Reduction in Nursing/Pharmacist Costs (2011) (1)
Breaking the therapeutic drug monitoring logistics barrier. (2014) (1)
315: Pharmacokinetics (PK) of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (AlloSCT) recipients (2007) (1)
Pharmacokinetics (PK) Of IV And Po Mycophenolate Mofetil (MMF) In Age Adjusted Pediatric And Adolescent Allogeneic Stem Cell Transplant (AlloSCT) Recipients: Significantly Higher CLss AND Vss IN PATIENTS <6 YEARS OF AGE (2009) (1)
Featured Article Profiling the dynamics of CSF and plasma Ab reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor (2016) (1)
THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN)-ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) COMPARISON STUDY: CHALLENGES AND OPPORTUNITIES (2018) (1)
More on Methanol-Associated Matrix Effects in Electrospray Ionization Mass Spectrometry (2009) (1)
Characterization of chromatin prepared from the erythrocytes of the common bloodworm glycera dibranchiata (1972) (1)
Area Under the Curve Bioequivalence of Mycophenolate Mofetil: CellCept® vs Generic (2010) (1)
DEVELOPMENT OF A FULLY AUTOMATED CSA METHOD FOR THE DIMENSION® CLINICAL CHEMISTRY SYSTEM. (1999) (1)
Review Article Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research (2014) (1)
CHOLESTEROL EFFLUX CAPACITY (CEC) IN PLASMA AND CEREBROSPINAL FLUID (CSF) OF PATIENTS WITH ALZHEIMER’S DISEASE (AD) AND MILD COGNITIVE IMPAIRMENT (MCI) AND COMPARISON SUBJECTS: EFFECTS OF GENDER AND DIAGNOSIS (2018) (1)
ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS (2018) (1)
CEREBROSPINAL FLUID LEVELS OF AMYLOID BETA AND TAU AS ENDOPHENOTYPES REVEAL NOVEL VARIANTS POTENTIALLY INFORMATIVE FOR ALZHEIMER'S DISEASE (2016) (1)
Digoxin Therapeutic Drug Monitoring in Outpatients (1993) (1)
P3-093: Characterization of CSF Aβ1-42, Tau and p-Tau181p concentrations at baseline in Alzheimer's disease neuroimaging initiative study patients (2008) (1)
Genome-wide association study of CSF biomarkers amyloid beta 1-42, tau and tau phosphorylated at threonine 181 in the ADNI cohort (2010) (1)
DERIVING A CUT-OFF FOR THE ELECSYS® β-AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER’S DISEASE (AD) (2017) (1)
Regulation of α6β1 Integrin-Mediated Migration in Macrophages (1995) (1)
Mycophenolate Mofetil Therapeutic Drug Monitoring: Combined Multi-linear Regression and Bayesian Limited Sampling Area Under the Curve versus Standard Care (2010) (1)
Heritability of regional brain volumes in large-scale neuroimaging and genetic studies (2017) (1)
VALIDATION STUDIES OF NEUROFILAMENT LIGHT AND Aβ-40 AND Aβ-42 ASSAYS IN HUMAN PLASMA USING THE SIMOA PLATFORM (2019) (1)
Thyroid, and Adrenal-Function Tests in Man (1976) (1)
Hydrolysisof Glutathioneby Human Liver ‘ y-Glutamyltransferase (2004) (1)
Two-Directional Immunoelectrophoresis: Technique and Applications in the Clinical Laboratory (1973) (1)
Effect of a variable magnetic field on clinical laboratory testing. (2009) (1)
Rifampicin Can Alter Pharmacokinetics Of Busulfan in Patients Given Bone Marrow Transplantation: 167 (2005) (1)
Unregulated self-medication in an ambulatory surgery population. (1993) (1)
PARIETAL LOBE CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH LOWER CEREBROSPINAL FLUID BETA AMYLOID 1-42 IN PATIENTS WITH SPORADIC AD (2018) (1)
Injury and Disease Linkages Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative * (2014) (1)
LIMITED SAMPLING STRATEGY FOR ESTIMATION OF MPA AUC IN PATIENTS RECEIVING CONCOMITANT SIROLIMUS. (2006) (1)
Bayesian Optimal Sampling Model (OSM) For Pharmacokinetic (PK) Individualization of Oral and Intravenous Busulfan (B) Regimens (2003) (1)
Identification of NPTX2 as a prognostic biomarker of Alzheimer’s disease through a longitudinal CSF proteomics study in ADNI subjects (2020) (1)
Cerebrospinal Fluid Biomarkers and [11C]Pittsburgh Compound-B PET Concordance in Alzheimer Disease vs. Frontotemporal Dementia Syndromes (P1.213) (2015) (1)
Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease. (2016) (1)
Title Large-scale genomics unveil polygenic architecture of human cortical surface area Permalink (2015) (0)
Improving analytical performance of immunoassay methods (2013) (0)
Review Articles The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans (2010) (0)
TransferabilityStudiesfor the AACC ReferenceMethodand the IFCC Methodfor Measurementof Alkaline PhosphataseActivity (1984) (0)
First Multicenter Qualification of an Assay (INNO-BIA Plasma Aß Forms Assay) for Measurement of ß-amyloid Proteins as Part of US-ADNI Efforts for Biomarker Qualification (2010) (0)
MetastasisPromotes Mammary Tumor Suppression of Insulin Receptor Substrate (2014) (0)
Cognitive performance characteristics of individuals with normal or pathological CSF and MRI biomarkers of Alzheimer's disease (2009) (0)
Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
Phosphorylated Tau Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis (P1.088) (2014) (0)
PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR AB1-42 (2016) (0)
3-D mapping of associations amongst amyloid-PET and CSF biomarkers and hippocampal morphology (2009) (0)
Modification of lidocaine protein binding with CO <Subscript>2 </Subscript> (2008) (0)
Comparison Of Free MPA Results from Two Methods: HPLC Tandem Mass Spectrometry and HPLC Single Mass Spectrometry: 149 (2005) (0)
CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE (2017) (0)
Analysis of the Urinary Isoprostane 8-Isopgf2?? Using HPLC With Tandem Mass Spectrometric Detection: 148 (2005) (0)
STANDARDIZATION OF AMYLOID BETA 42 IN-HOUSE CALIBRATORS FOR A REFERENCE LC-MS-MS METHOD FOR ANALYSIS OF AMYLOID BETA 42 IN HUMAN CSF, USING THREE AVAILABLE CERTIFIED REFERENCE MATERIALS (2019) (0)
Biochemical Biomarkers of Depressive Symptoms in ADNI (2011) (0)
IMPACT OF ANALYTICAL BIAS AND IMPRECISION OF CSF BIOMARKERS ON THEIR CLINICAL DIAGNOSTIC PERFORMANCE FOR AD DIAGNOSIS (2014) (0)
The ADNI multicenter study: CSF biomarkers data report (2009) (0)
60 MYCOPHENOLIC ACID MEASUREMENT IN PLASMA: VALIDATION OF AN HPLC METHOD BY COMPARISON WITH AN HPLC-MASS SPECTROMETRY PROCEDURE (1997) (0)
THE MULTIDOMAIN IMPAIRMENT RATING (MIR) SCALE: INITIAL RELIABILITY DATA ON A MULTIDIMENSIONAL SCALE DESIGNED FOR FTLD SPECTRUM DISORDERS (2019) (0)
ANALYTICAL AND CLINICAL PERFORMANCE OF AMYLOID BETA PEPTIDES: MEASUREMENT IN CSF OF ADNI2 AND GO PARTICIPANTS BY A LC-MS-MS REFERENCE METHOD (2018) (0)
Presence of Brain Amyloidosis Can Be Ascertained from Cognitive, Imaging and Peripheral Blood Protein Measures (IN3-1.004) (2013) (0)
Featured Article The transitional association between b-amyloid pathology and regional brain atrophy (2015) (0)
Abstract B043: Role of IRS2-microtubule interactions in breast carcinoma cell survival (2013) (0)
Electrophoretic , Kinetic , and ImmunoinhibitionPropertiesof y-Glutamyltransferasefrom VariousTissuesCompared (2004) (0)
Regional variations in brain atrophy, CSF biomarkers and ApoE relations (2010) (0)
INTERNATIONAL ROUND ROBIN ON SRM TRIPLE QUAD MASS SPECTROMETRIC ANALYSIS OF Aβ42 IN CEREBROSPINAL FLUID (2014) (0)
Brain changes in 676 ADNI subjects: Summary of 10 studies using tensor based morphometry and automated hippocampal mapping (2009) (0)
Cocaine Detection in Peritoneal Dialysis Fluid. (2017) (0)
Effect of cocaine and cocaine metabolites on the cerebral microvasculature in piglets (1992) (0)
P-057 Validation of the xMAP technology and performance of INNO-BIA AlzBio3 for quantification in CSF of Aβ1-42, total tau and P-tau181p (2007) (0)
CSF α-synuclein, BETA-AMYLOID 1-42 and tau proteins: Relationship to clinical parameters in early Parkinson's disease (2012) (0)
USE FOR CALIBRATION OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42 (2017) (0)
P3‐013: Withdrawn (2015) (0)
Higher CSF STREM2/P‐tau ratio levels attenuate effects of polygenic Alzheimer’s disease risk on cognitive decline and neurodegeneration (2020) (0)
False-negative results in urine benzodiazepine immunoassay screening (2020) (0)
Guidelines to consider when buying generic drugs for worksite dispensing. United States Food and Drug Administration. (1992) (0)
Learning from Our Mistakes: APOE4 Influences Misdiagnosis of Alzheimer’s Disease and Frontotemporal Degeneration (P5.208) (2014) (0)
STRESS LEVEL IS ASSOCIATED WITH ALZHEIMER’S DISEASE CSF BIOMARKERS AND COGNITION ESPECIALLY IN AFRICAN AMERICANS WITH MILD COGNITIVE IMPAIRMENT (2019) (0)
USING A BRAIN NETWORK APPROACH TO PREDICT GENETIC MUTATION IN INDIVIDUAL PATIENTS WITH FAMILIAL FRONTOTEMPORAL DEMENTIA (2018) (0)
Illustratedby Aminotransf erase Assays (1975) (0)
Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days In Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Pharmacokinetically Similar to Q6 Hour Dosing in the Pediatric Population (2009) (0)
MULTIVARIATE GENOME-WIDE ASSOCIATION STUDY OF CSF BIOMARKERS FOR ALZHEIMER’S DISEASE IDENTIFIES VARIANTS IN HLA CLASS I REGION PROVIDING FURTHER EVIDENCE FOR THE ROLE OF IMMUNE FUNCTION (2018) (0)
SERUM TRIGLYCERIDES IN ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING, CSF, AND GENETIC VARIATION (2019) (0)
PharmacokineticAnalysis of a Case of IsopropanolIntoxication (1985) (0)
THE CONTRIBUTION OF SEX-SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER’S DISEASE PATHOLOGY (2018) (0)
Cocaethylene Levels in Patients Treated for Major Trauma (1993) (0)
Correlation of Oncotype DX Recurrence Score With the Expression of Insulin Receptor Substrate Proteins in Estrogen Receptor + Breast Cancer (2014) (0)
Abstract 3524: Unraveling the dichotomy of Runx1 in breast cancer (2014) (0)
Use of CSF biomarkers in clinical trials: The ADNI experience (2011) (0)
Abstract #4402: Specific contributions of Irs-1 and Irs-2 in regulating mammary tumor metastasis (2009) (0)
A-79Primacy-Weighted Retrieval Differences in Healthy Older Adults with Pathological or Normal Cerebrospinal Fluid Markers of Alzheimer's Disease (2014) (0)
A MULTI-CENTER EVALUATION OF THE RELATIONSHIP OF TACROLIMUS BLOOD LEVELS TO EFFICACY AND TOXICITY IN LIVER TRANSPLANT PATIENTS. (1999) (0)
CSF AD BIOMARKER CHANGES AND COGNITIVE CHANGE AFTER SURGERY IN OLDER ADULTS (2019) (0)
The Role of Age and Genetic Markers on Cerebrospinal Fluid Tau Levels in Pathology-Confirmed Frontotemporal Degeneration (P1.219) (2015) (0)
eScholarship Title Clinical and multimodal biomarker correlates of ADNI neuropathological findings Permalink (2013) (0)
Analysis of the role of Y1494 in α6β4 integrin-mediated breast carcinoma progression. (2007) (0)
Electrophoretic, Kinetic,andImmunoinhibition Properties of y-Glutamyltransferase fromVariousTissues Compared (1980) (0)
H. pylori activates the EGF receptor to regulate IL-8 gene expression in AGS gastric epithelial cells (2001) (0)
Books Received (2005) (0)
Ultra-performance 2D-liquid chromatography–tandem mass spectrometry method for simultaneous analysis of beta-amyloid peptides: 1-38, 1-40 and 1-42 in human cerebrospinal fluid (2012) (0)
The Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol: Known Kindreds and Preliminary Data (P5.003) (2015) (0)
Evidence that Distinct States of the Integrin (cid:97) 6 (cid:98) 1 Interact with Laminin and an ADAM (1999) (0)
Clinical Pharmacology of Mycophenolic Acid as Immunosuppressant in Organ Transplaantation (2005) (0)
Brain Aβ amyloid measures and MRI are complimentary predictors of progression from MCI to Alzheimer's disease (2010) (0)
IRS-1 and microRNAs: Partners in growth regulation (2009) (0)
Amifostine does not protect against liver toxicity in patients receiving dose-escalated IV busulfan (IVBU) and standard dose cyclophosphamide in auto BMT (2006) (0)
The Alzheimer’s metabolome: Identification of novel markers and treatment targets (2015) (0)
Ultra‐performance liquid chromatography‐tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture (2020) (0)
Increased Cerebrospinal Fluid Total-Tau Levels in Hereditary Behavioral-Variant Frontotemporal Dementia (P5.030) (2015) (0)
Comparing predictors of conversion: Data from the Alzheimer's Disease Neuroimaging Initiative (2009) (0)
APPROPRIATE USE CRITERIA FOR LUMBAR PUNCTURE AND CEREBROSPINAL FLUID TESTING IN THE DIAGNOSIS OF ALZHEIMER’S DISEASE (2018) (0)
ANALYSIS OF MYCOPHENOLIC ACID PHARMACOKINETICS IN AFRICAN AMERICAN AND CAUCASIAN RENAL TRANSPLANT RECIPIENTS (1998) (0)
HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α-SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH (2018) (0)
Proceedings of the Analytica Conference 2000 Symposium on Laboratory Evaluation and Monitoring of Transplant Recipients (2001) (0)
JCB_201404118 1..17 (2014) (0)
THE TRACE AMOUNT OF MYCOPHENOLIC ACID IN IT'S PHENOLIC GLUCURONIDE EXPLAINS THE WEAK INHIBITION OF IMPDH BY THE METABOLITE. (1999) (0)
Biomarker Based Diagnosis Of Very Mild Alzheimer'S Disease: A Multicenter Study (2009) (0)
Effect Of Theophylline (THEO) On Cerebral Blood Flow (CBF) And Energy Metabolism Response To Asphyxia In Newborn Piglets (NB). (1990) (0)
Brain changes in 676 ADNI subjects: summary of 10 studies using tensor based-morphometry and automated hippocampal mapping (2009) (0)
193 FREE MYCOPHENOLIC ACID PHARMACOKINETICS (PK) IN RENAL TRANSPLANT PATIENTS EARLY AFTER SURGERY (1996) (0)
Anxiety is related to Alzheimer's disease markers in cerebrospinal fluid of subjects with mild cognitive impairment (2011) (0)
INTRODUCTION (1982) (0)
Influence of rare RELN variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer’s disease (2015) (0)
Reaction-Rate Methodfor #yGIutamyItransferase Activityin Serum (1976) (0)
PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42 (2017) (0)
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment (2010) (0)
Featured Articles Improved protocol for measurement of plasma b-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients (2012) (0)
ATN classifications in a mixed cohort of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD) pathology using cerebrospinal fluid neurofilament light chain (NFL) (2020) (0)
O-methylated rapamycin derivatives for alleviating or preventing lymphoproliferative disorders (2001) (0)
LaboratoryAssessment of Poisoningwith a Carbamate Insecticide (1988) (0)
WHOLE GENE-BASED ASSOCIATION OF BASELINE PLASMA HOMOCYSTEINE IN THE ADNI-1 COHORT (2014) (0)
Regulation of ct6B1 Integrin Laminin Receptor Function by the Cytoplasmic Domain of the ct6 Subunit (2002) (0)
TOWARD RE-CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ42 IN HUMAN CEREBROSPINAL FLUID (2019) (0)
A Retrospective Analysis Of Risk Factors That Influence Intravenous Busulfan Kinetics In Adult Patients (2009) (0)
NOVEL CSF BIOMARKERS OF NEURONAL INJURY, SYNAPTIC DYSFUNCTION AND NEUROINFLAMMATION IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: VILIP-1, NEUROGRANIN, SNAP-25 AND YKL-40 IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN) (2018) (0)
Higher clearance rates of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (allosct) recipients (2006) (0)
The path to regulatory qualification of cerebrospinal fluid biomarkers as enrichment tools in clinical trials of patients with early Alzheimer’s disease: For the coalition against major diseases (2015) (0)
P1-318 PLASMA NUTRIENT STATUS OF ALZHEIMER'S DISEASE PATIENTS COMPARED TO COGNITIVE INTACT ELDERLY CONTROLS: A SYSTEMATIC (2011) (0)
O-methylated derivatives of rapamycin for alleviating and inhibiting disorders. (2001) (0)
TRACKING WHITE MATTER DEGENERATION IN ASYMPTOMATIC AND SYMPTOMATIC MAPT MUTATION CARRIERS WITH DTI (2019) (0)
Predictability of pretransplant intravenous busulfan (IVBU) PK data in achieving targeted IVBU AUC’s during conditioning in auto BMT (2006) (0)
Online Exclusive Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology (2013) (0)
Worldwide ADNI Update – July , 2012 (2013) (0)
Comparing MRI and CSF biomarkers in Alzheimer's disease: Intergroup discrimination and predicting clinical change (2009) (0)
Measurement of OG37-325 by high-performance liquid chromatography. (1994) (0)
PHARMACOGENETIC FACTORS AFFECTING MYCOPHENOLATE MOFETIL (MMF) PHARMACOKINETIC AND PHARMACODYNAMIC VARIABILITY IN THE OPTICEPT KIDNEY TRANSPLANT STUDY: PRELIMINARY ANALYSIS: 2759 (2010) (0)
O1-10-03 AN ACTIVE ANTI-AB40 VACCINE (ABVAC40) PROVED TO BE SAFE AND IMMUNOGENIC IN THE PHASE I CLINICAL TRIAL (2019) (0)
1991-P: Mammary Tumors Increase Diet-Induced Obesity and Insulin Resistance in Female MMTV-PyMT Mice (2019) (0)
Cervical cancer: a two-pronged attack. (1984) (0)
CSF Aβ1-42-an excellent but complicated Alzheimer biomarker-the IFCC WG-CSF route to standardisation (2018) (0)
High mitochondrial DNA in cerebrospinal fluid is associated with LRRK2-related Parkinson's disease (2017) (0)
PROGRESS IN STANDARDIZATION AND IMPLEMENTATION OF CSF BIOMARKERS IN CLINICAL TRIALS AND ROUTINE PRACTICE (2016) (0)
The effect of Propofol versus Isoflurane Anesthesia on Human CSF Markers of Alzheimer ’ s Disease : Results of a Randomized Trial (2015) (0)
CHARACTERISTICS AND PROGRESS OF 320 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL (2018) (0)
Determinationof Procainamideand N-Acetylprocainamideby "High- Pertormance" Liquid Chromatography (1981) (0)
FactorsAffecting the Bindingof Disopyramide to SerumProteins (1985) (0)
ASSAY PERFORMANCE MONITORING FOR AD BIOMARKERS USING POOLED CEREBROSPINAL FLUID (2018) (0)
Regulation of ct 6 B 1 Integrin Laminin Receptor Function by the Cytoplasmic Domain of the ct 6 Subunit (2002) (0)
The Effect of Cocaine on the Acid-Base Balance of Trauma Patients (1993) (0)
INCREASED CSF SOLUBLE TREM2 IS ASSOCIATED WITH AMELIORATED LONGITUDINAL COGNITIVE AND CLINICAL DECLINE IN ALZHEIMER'S DISEASE (2019) (0)
NEURODEGENERATION IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE (0)
IRS-2 signaling to AKT determines response to microtubule disruption in breast carcinoma cells (2017) (0)
Oral Sessions: O3-03: Biomarkers: Temporal Sequence of Biomarkers (2013) (0)
A candidate reference method for analysis of amyloid beta 1-42 (Aß1-42) peptide in human CSF using 2D-HPLC with a xevo t q-s mass spectrometer (2015) (0)
DIFFERENTIAL EFFECT OF PROSPECTIVE ESCITALOPRAM DECREASE ON LONGITUDINAL CSF AB CONCENTRATION IN AMYLOID (+) VERSUS AMYLOID (-) COGNITIVELY NORMAL ELDERLY INDIVIDUALS (2018) (0)
Pharmacokinetics Of Mycophenolate Mofetil (MMF) In Combination With Tacrolimus In Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients≤12 Years Of Age (2010) (0)
Mitochondrial DNA in cerebrospinal fluid distinguishes idiopathic from LRRK2-related Parkinson's disease (2017) (0)
Intravenous (IV) Busulfan (Bu) Administered Twice Daily During Conditioning Prior to Allogeneic Stem Cell Transplant (AlloSCT) in Pediatric Recipients Has Significantly Different Half-Life of Elimination and Clearance in Recipients >4 Years and Those ≤ 4 Years (2012) (0)
SY2-2: The IRS proteins: determinants of IGF-1R signaling and tumor metabolism (2014) (0)
CHANGES IN HOMOCYSTEINE CONCENTRATION AFTER ORTHOTOPIC HEART TRANSPLANTATION (1998) (0)
Erratum: CSF biomarker variability in the Alzheimer's Association quality control program (Alzheimer's and Dementia (2013) 9 (251-261)) (2015) (0)
Ultrasensitive, High Throughput HPLC-MS/MS Method For Everolimus (RAD) Measurement; Comparison Of Two Internal Standards: SDZ RAD 223-765 And Ascomycin: 79 (2005) (0)
Comparison of Amyloid PET and CSF Biomarkers in the Evaluation of Dementia (PD1.004) (2012) (0)
Drug Development for Neurodegenerative Diseases Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating (2014) (0)
Human pharmacokinetics (PHARM) of WR-2721 (WR) by electrochemical detection and high pressure liquid chromatography (HPLC) (1984) (0)
Comparing MRI and CSF biomarkers in Alzheimer's disease: Intergroup discrimination and predicting clinical change (2009) (0)
Activation ofJak/STATproteins involved insignal transduction pathwaymediated byreceptor forinterleukin 2inmalignant T lymphocytes derived fromcutaneous anaplastic largeT-cell lymphomaandSezary syndrome (1996) (0)
Investigator and Core Facility Contact Information (2012) (0)
PROSPECTIVE ESCITALOPRAM DECREASES LONGITUDINAL CSF Aβ CONCENTRATION IN COGNITIVELY NORMAL ELDERLY SUBJECTS: A RANDOMIZED DOSE FINDING STUDY (2017) (0)
CSF p‐Tau/AΒ40 ratio adjusts for the variance of CSF production and predicts brain tau accumulation in Alzheimer’s disease (2020) (0)
Application of Response Surface Methodology to the Assay of Gamma-Glutamyltransf erase (2004) (0)
CSF BIOMARKER CORRELATES OF ARTAG NEUROPATHOLOGY (2019) (0)
Developmentof a Stable ReferenceMaterialfor ProstaticAcid Phosphatase (1984) (0)
Two-Directional Immunoelectrophoresis (1972) (0)
Regulation of Breast Carcinoma Progression by the Alpha-6 Integrins (2000) (0)
The impact of pre-analytical variables on measuring CSF biomarkers for Alzheimer’s disease diagnosis: A review (2019) (0)
Qualification of a surrogate matrix-based absolute quantification method for beta-amyloid peptides in human CSF using 2D UPLC-SRM mass spectrometry (2013) (0)
Books Received (2005) (0)
ORAL SESSIONS O3-14 BIOMARKERS: NOVEL BIOMARKERS IN CEREBROSPINAL FLUID (CSF) O3-14-01 NOVEL CSF BIOMARKERS OF NEURONAL INJURY, SYNAPTIC DYSFUNCTION AND NEUROINFLAMMATION IN AUTOSOMAL DOMINANTALZHEIMER DISEASE: VILIP-1, NEUROGRANIN, SNAP-25 AND YKL-40 IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK (D (2018) (0)
The certification of Amyloid β 1-42 in CSF in ERM ®-DA 480 / IFCC , ERM ®-DA 481 / IFCC and ERM ®-DA 482 / IFCC (2017) (0)
3D mapping of associations amongst amyloid-PET and CSF biomarkers and hippocampal morphology (2009) (0)
THE ALZHEIMER’S METABOLOME: RELATIONSHIP TO PATHOLOGICAL MARKERS AND COGNITIVE DECLINE IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) (2016) (0)
Improving Diagnostic Accuracy for Dementia: CSF Biomarker Cutoffs Based on Clinical and Neuropathological Criteria (IN3-1.010) (2012) (0)
2 Day Symposium to celebrate the career of Professor David W Holt (2010) (0)
TBK1 has a new Akt (2021) (0)
FRONTOTEMPORAL LOBAR DEGENERATION RESEARCH IN NORTH AMERICA: PROGRESS IN THE ARTFL/LEFFTDS CONSORTIA (2019) (0)
158 A PHARMACOKINETIC STUDY OF PACLITAXEL IN PATIENTS WITH METASTATIC COLORECTAL CANCER (1995) (0)
Measurement of plasma gamma glutamyl transferases activities and standardization (1981) (0)
The Role of Integrin Signaling in Breast Cancer. (1997) (0)
Abstract 3291: Upregulation of Insulin Receptor Substrate-2 (IRS-2) expression by hypoxia (2010) (0)
76 MYCOPHENOLIC ACID BINDING TO PLASMA PROTEINS MODULATES ITS PHARMACOLOGIC ACTIVITY (1995) (0)
Featured Article Round robin test on quantification of amyloid-b 1-42 in cerebrospinal fluid by mass spectrometry (2016) (0)
Predictive Performance of CSF Biomarkers for Conversion from Mild Cognitive Impairment to Alzheimer's Disease (2012) (0)
FV 3 Analysis of cerebrospinal fluid (CSF) biomarkers to predict risk of clinical decline and progression to dementia in patients with mild cognitive impairment and mild cognitive symptoms (2019) (0)
Comparative Clinical Bioavailability of Delta-9-THC from a Suppository Formulation Containing the Hemisuccinate Ester vs. an Oral Preparation (1993) (0)
Effect of Dopamine Antagonism on Tissue Blood Flow Response to Cocaine (1994) (0)
Regulation of Breast Carcinoma Progresssion by the Integrins. (1998) (0)
MPA protein Binding in Uremic Plasma: Prediction of Free Fraction (1999) (0)
ANALYSIS OF PROTEIN-BOUND AND TOTAL S-2-(3-AMINOPROPYLAMINO)ETHANETHIOL (WR-1065) IN BLOOD BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC). (1999) (0)
Optimal alpha-oxobutyrate concentration for assay of alpha-hydroxybutyrate dehydrogenase activity in normal and pathological sera at 30 degrees C. (1974) (0)
Web‐based requisitioning, tracking and laboratory result reporting system for clinical trials using a central laboratory (2020) (0)
COMPARISON OF FLORTAUCIPIR PET WITH CEREBROSPINAL FLUID, COGNITIVE FUNCTIONING AND NEUROIMAGING MEASURES IN MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (2019) (0)
Pharmacokinetics (PK) of Mycophenolate Mofetil (MMF) in Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients Are Associated with Significantly Higher Clearance. (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Leslie Michael Shaw?

Leslie Michael Shaw is affiliated with the following schools:

Leslie Michael Shaw's Academic­Influence.com Rankings